Filing Flows

Filing Flows › 8-K events › Enanta Pharmaceuticals

Enanta Pharmaceuticals: departure or appointment of directors and officers

Form 8-K filed Oct 28, 2026 · items 5.02, 7.01

CEO changesEnanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

What the filing says

On October 28, 2026, Enanta Pharmaceuticals, Inc. (the “Company”) and Jay R. Luly, Ph.D., age 70, announced Dr.

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Enanta Pharmaceuticals at a glance

Latest quarterQ3 FY26
Revenue$14.4M
Revenue Y/Y-22%
Operating margin-120.0%
IndustryPharmaceutical Preparations

Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%. The chart follows the revenue to costs, profit and cash.

Enanta Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.